Back

Early haemodynamic response but persistent systolic dysfunction after mavacamten interruption in obstructive hypertrophic cardiomyopathy (oHCM): a pharmacist led titration case

28 August 2026 (10:45 - 10:57)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: from diagnosis to therapy Clinical ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Deepa Lakhani

Imperial College Healthcare NHS Trust, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
A young female patient with massive LVH and dual-level obstructive HCM: a case report on the successful use of mavacamten and future management planning
Doctor D. Da Silva Correia (Lisbon, PT)
Slides Video
Presentation thumbnail
Unusual genetics in hypertrophic cardiomyopathy: looking beyond autosomal dominant inheritance
Doctor S. Rivas Garcia (Madrid, ES)
Slides Video
Presentation thumbnail
Hypertrophic cardiomyopathy phenotype associated with concomitant gla, ttr and prkag2 variants in an amazonian adolescent
Doctor I. Peterlini Valsi (Sao Paulo, BR)
Slides Video
Presentation thumbnail
Mavacamten for worsening left ventricular outflow tract obstruction after TAVI in a patient with hypertrophic cardiomyopathy
Mr M. Takeuchi (Nankoku, JP)
Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: from diagnosis to therapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 10:45 CET
You may be interested in
thumbnail
Congress Presentation
Effects of Mavacamten use in a patient with hypertrophic obstructive cardiomyopathy and extremely high resting left ventricular outflow tract gradient
9 May 2026
thumbnail
Congress Presentation
When relief turns risk: a case of mavacamten overexposure in obstructive HCM.
13 December 2025
thumbnail
Congress Presentation
New and emerging treatment options for HCM
12 May 2023
thumbnail
Congress Presentation
Hypertensive crisis following Mavacamten introduction in severe obstructive Hypertrophic Cardiomyopathy and arterial hypertension
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources